Home » FDA Rejects Intarcia's Drug Pump for Treatment of Type 2 Diabetes
FDA Rejects Intarcia's Drug Pump for Treatment of Type 2 Diabetes
The FDA rejected Intarica Therapeutics’s manufacturing plan for a matchstick-sized drug pump for the treatment of Type 2 diabetes.
The ITCA 650 device is inserted into the abdomen and gradually pumps tiny amounts of a drug into the bloodstream over the course of six months or a year.
The device outperformed Merck’s blockbuster drug, Januvia, in a head-to-head trial last year.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May